---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-015846"
form_type: "8-K"
ticker: null
cik: "0001817944"
company_name: "Clarus Therapeutics Holdings, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:38:51.746717+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Clarus Therapeutics completes Chapter 11 liquidation; all common stock cancelled

## Summary
- Plan effective Feb 28, 2023; all outstanding common stock cancelled and discharged.
- Board of directors dissolved as of the Effective Date.
- Company intends to file Form 15 to deregister securities and suspend SEC reporting.
- Previously sold JATENZO assets to Tolmar in Oct 2022; sale approved by bankruptcy court.
- Clarus will cease periodic reporting obligations upon Form 15 filing.

## SEC filing metadata
- accession: 0001213900-23-015846
- form_type: 8-K
- cik: 0001817944
- company_name: Clarus Therapeutics Holdings, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.03, 2.01, 3.03, 5.01, 5.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/0001213900-23-015846-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/ea174454-8k_clarus.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-015846
- JSON: https://secwatch.observer/filing/0001213900-23-015846.json
- Plain text: https://secwatch.observer/filing/0001213900-23-015846.txt

## Key facts
- Distress & Bankruptcy
  Clarus Therapeutics Holdings, Inc. entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2022-09-05).
  - Proceeding: chapter 11
  - Court: United States Bankruptcy Court for the District of Delaware
  - Petition: 2022-09-05
  source text: Clarus Therapeutics Holdings, Inc., or Clarus, and its wholly-owned subsidiary Clarus Therapeutics, Inc., or OpCo, filed voluntary petitions for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware, or the Court (Case No. 22-10845).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/0001213900-23-015846-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.